



DanCann Pharma A/S' shares commence trading on the OTCQB venture market in the United States

COPENHAGEN, Denmark, 5 December 2022 - DanCann Pharma A/S (SS: DANCAN) ("DanCann Pharma" or the "Company"), a Danish company powered by cannabinoids, hereby announces that the Company has been welcomed by OTC Markets Group for trading on OTCQB in the US - an important step for DanCann Pharma into the US capital markets improving access for US-Investors to DCPXF-shares.

DanCann Pharma has been approved and qualified to trade on the OTCQB Venture Market under the symbol "DCPXF". OTC Markets Group is an operator of regulated markets for trading 12,000 US and international securities providing international companies with the opportunity to make their shares more easily accessible to US investors. US investors can now find the current financial disclosures and real-time level two (2) quotes for DanCann Pharma on www.otcmarkets.com.

The trading on OTCQB marks an important step for DanCann Pharma in providing more transparent trading and tapping demand from US investors. The purpose is to increase visibility and accessibility in the US capital market thereby providing greater liquidity and value to the Company's shareholders.

Jeppe Krog Rasmussen, Founder and CEO of DanCann Pharma, comments:

- The timing is perfect. We have just received EU-GMP-approval of our high-end production facilities Biotech Pharm1 and is ready to start production of biomaterial for export. As we continue to grow and wish to position DanCann Pharma as a leading contributor to the medicinal cannabis market, we have experienced considerable interest over time in the Company from US-based investors. To leverage on this interest and increase visibility and accessibility in the US capital market, we decided to join the OTCQB market. We are looking forward to the opportunities this will bring to the Company, as well as the value we believe it will bring for our shareholders.

As DanCann Pharma is listed on a qualified foreign exchange already (Spotlight Stock Market), the streamlined market standards enable DanCann Pharma to utilize the home market reporting to make company information available in the US through OTCQB. To qualify for trading, DanCann Pharma has meet financial standards, follow best practice corporate governance, and has demonstrated compliance with applicable security laws.



Shares traded on the OTCQB market is sourced via the Spotlight Stock Market (Scale Segment), which is expected to have a positive effect on the overall trading of the DanCann Pharma shares. Joining the OTCQB venture market will facilitate US investors to trade in DanCann Pharma's ordinary share in US dollars, with a US ticker symbol (DCPXF), and during US market hours.

Jeppe Krog Rasmussen comments:

- DanCann Pharma is uniquely positioned as a Danish/European company working within medicinal cannabis and therapeutic cannabinoids. The company is not backed by joint venture constellations or other funding from the USA or Canada. DanCann Pharma already hold a number of permits and has signed collaboration agreements with producers and distributors in Europa and North America. We believe there is latent interest at the US markets to invest in our Company's progress.

DanCann Pharma's share remains listed – and will continue to trade – on the Spotlight Stock Exchange and no new ordinary shares will be issued as part of the process. Joining the OTCQB venture market will allow easier trading access for US investors, which the company believes will increase liquidity and revenue in the share as well as the possibility to broaden the shareholder base. North America is a world leader within biotech and cannabis which makes investing in an established and fast-moving Danish market contributor even more relevant.

Jeppe Krog Rasmussen elaborates:

- So far, we have had a successful journey based on a large number of loyal investors. However, as DanCann Pharma is increasing in size and professionalism, we wish to reflect this in our investor-base. We hope that our introduction in the US venture market will open for a number of semi- institutional and in the future looking towards more institutional investors. The OTCQB dual quotation marks an important step in our effort to provide US investors with easier access to the DanCann Pharma share. US investors can now – finally - trade the DanCann Pharma share in US dollars and during US hours.



DanCann Pharma

About OTC Markets Group Inc.

OTC Markets Group Inc. (OTCQX: OTCM) operates regulated markets for trading 12,000 U.S. and international securities. Our data-driven disclosure standards form the foundation of our three public markets: OTCQX(R) Best Market, OTCQB(R) Venture Market and Pink(R) Open Market. Our OTC Link(R) Alternative Trading Systems (ATSs) provide critical market infrastructure that broker-dealers rely on to facilitate trading. Our innovative model offers companies more efficient access to the U.S. financial markets. OTC Link ATS, OTC Link ECN and OTC Link NQB are each an SEC regulated ATS, operated by OTC Link LLC, a FINRA and SEC registered broker-dealer, member SIPC. To learn more about how we create better informed and more efficient markets, visit www.otcmarkets.com.

About DanCann Pharma

DanCann Pharma A/S (SS: DANCAN) was founded in 2018 and is a Danish biopharmaceutical Company powered by cannabinoids. DanCann Pharma is a vertically integrated, licensed production and distribution Company based in Denmark. The Company focuses on discovering, developing, manufacturing, and commercializing new therapeutic cannabinoids in a wide range of disease areas. DanCann Pharma A/S (SS: DANCAN) is listed on the Spotlight Stock Market in Copenhagen.

For more information, visit: www.dancann.com.

For further information, please contact:

Jeppe Krog Rasmussen, CEO

E-mail: jkr@dancann.com

Website: www.dancann.com

Forward looking statement

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events, or developments that the Company believes, expects, or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words "may", "will", "should", "continue", "expect", "anticipate", "estimate", "believe", "intend", "plan" or "project" or the negative of these words or other variations on these words or comparable terminology.

Forward-looking statements are subject to several risks and uncertainties, many of which are beyond the Company's ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, to obtain sufficient financing to execute the Company's business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company's research strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company's public disclosure record on file with the relevant securities regulatory authorities.

Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this presentation are made as of the date of this presentation and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.